Sangamo BioSciences Mergers and Acquisitions Summary

Life Science Company

Sangamo BioSciences has acquired 4 companies, including 1 in the last 5 years. A total of 1 acquisition came from private equity firms.

Sangamo BioSciences’ largest acquisition to date was in 2018, when it acquired TxCell S.A. for $81M. Sangamo BioSciences has acquired in 1 US state, and 3 countries. The Company’s most targeted sectors include life science (100%).

Join Mergr and gain access to Sangamo BioSciences’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

M&A Summary

  • M&A Total Activity4
    • M&A Buy Activity4
  • Total Sectors Invested 1
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 2
  • M&A Advisors 1

Sangamo BioSciences, Inc.

501 Canal Boulevard,
Richmond, California 94804
United States,
(510) 970-6000
www.sangamo.com

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. Sangamo Therapeutics was founded in 1995 and is based in Richmond, California.


M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (0.2/yr) # 3 - 1 - - - 4
vol $40M $81M $121M
Sell (0.0/yr) # - - - - - - 0
  4

Most Recent M&A

Company Date Value Type
TxCell S.A. 2018-07-23 81M EUR Add-on Acquisition
Valbonne, France · www.txcell.com
Ceregene, Inc. 2013-08-26 - Add-on Acquisition
San Diego, California · www.ceregene.com/
Edwards Lifesciences Corp. - Angiogenesis Program 2006-12-04 - Divestiture
Irvine, California
Gendaq Ltd. 2001-05-30 40M USD Add-on Acquisition
London, United Kingdom
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 4 (100%) 121M (100%) - -
Total 4 $121M - -

By Geo

State/Country Buy Value Sell Value
United States 2 - - -
  California 2 - - -
France 1 81M - -
United Kingdom 1 40M - -
Domestic 2 (50%) - - -
Cross-border 2 (50%) 121M (100%) - -
Total 4 $121M - -

Top M&A Advisors

Financial Deals
Alantra Partners, S.A. - Investment Bank
1

Deal Values

buy # Total
< $100M 2 $121M
TOTAL $121M
Largest TxCell S.A.
$81M (2018-07-23)

M&A Connections

Deals
Acquired from
Investor(s)
25%
1 (25%)
Strategic(s)
25%
1 (25%)

 Subscribe to unlock this and 161,439
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.1K Private Equity Firms
  • 150K M&A Transactions
  • 157K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.2K M&A Advisors
    (Investment Banks and Law Firms)
  • 48K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.